Sort
82,697 grants matching “vaccine development”
Acquisition of a high resolution, high throughput cryo-electron microscope
$2,000,000Justin M Kollman · University Of Washington · S10 · FY2017 · OD
Nanovaccine for Eliciting bnAbs Against HIV-1
$2,000,000Santanu Raychaudhuri · Neovaxsyn, Inc. · N44 · FY2024 · AI
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
$2,000,000Hiiti Sillo · World Health Organization · U01 · FY2022 · FD
Increasing access to safe and effective products for the prevention, diagnosis and treatment of priority diseases, especially for use in low-and middle-income countries.
$2,000,000Hiiti Sillo · World Health Organization · U01 · FY2019 · FD
Leadership Group for a Global HIV Vaccine Clinical Trials Network
$2,000,000Lawrence Corey · Fred Hutchinson Cancer Research Center · U01 · FY2010 · AI
Safeguard the household: comprehensive AIDS research
$2,000,000Wits Health Consortium (Pty), Ltd · U19 · FY2004 · AI
Development of Fludase for Prevention of Influenza
$2,000,000Mang Yu · Nexbio, Inc. · R44 · FY2007 · AI
SPORE in Lung Cancer
$2,000,000Eric B. Haura · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2010 · CA
Meharry HIV/AIDS Research and Training Facility
$2,000,000Vladimir Berthaud · Meharry Medical College · C06 · FY2022 · OD
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
$2,000,000Nicolas Collins · Vaccine Formulation Institute (Ch) Ltd · N01 · FY2025 · AI
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
$2,000,000Hiiti Sillo · World Health Organization · U01 · FY2023 · FD
HPC & GPU Resources for AI/ML Augmented Biomedical Research
$2,000,000William Shane Sanders · Fred Hutchinson Cancer Center · S10 · FY2025 · OD
Increasing access to safe and effective products for the prevention, diagnosis and treatment of priority diseases, especially for use in low-and middle-income countries.
$2,000,000Michael Ward · World Health Organization · U01 · FY2018 · FD
Advancing Vaccine Adjuvant Research for Tuberculosis (TB)
$2,000,000Warwick Britton · University Of Sydney · N01 · FY2025 · AI
Increasing access to safe and effective products for the prevention, diagnosis and treatment of priority diseases, especially for use in low-and middle-income countries.
$2,000,000Michael Ward · World Health Organization · U01 · FY2017 · FD
SPORE in Lung Cancer
$2,000,000Eric B. Haura · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2009 · CA
SPORE in Lung Cancer
$2,000,000Gerold Bepler · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2008 · CA
Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
$2,000,000Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2022 · IP
Significant expansion of the SNPRC ABSL3 capability in the wake of COVID-19
$2,000,000Larry S. Schlesinger · Texas Biomedical Research Institute · P51 · FY2020 · OD
Development of Fludase for Prevention of Influenza
$2,000,000Mang Yu · Nexbio, Inc. · R44 · FY2006 · AI
CONSTRUCTION OF THE VACCINE CENTER
$2,000,000Children'S Hospital &Res Ctr At Oakland · C06 · FY2002 · RR
Safeguard the household: comprehensive AIDS research
$2,000,000James Alasdair McIntyre · Wits Health Consortium (Pty), Ltd · U19 · FY2006 · AI
RFA-CK-22-003, Emerging Infections Sentinel Networks (EISN) Research - 2022
$2,000,000David Andrew Talan · University Of California Los Angeles · U01 · FY2024 · CK
Development of Fludase for Prevention of Influenza
$2,000,000Nexbio, Inc. · R44 · FY2005 · AI
TUBERCULOSIS VACCINE DEVELOPMENT
$2,000,000Christopher Case · Leidos Biomedical Research, Inc. · N01 · FY2015 · CA